Genistein (DB01645): A Comprehensive Pharmacological and Therapeutic Monograph

Executive Summary

Genistein is a prominent, naturally occurring isoflavone, a class of organic compounds characterized by a distinctive chemical structure that allows them to interact with a wide array of biological systems.[1] Primarily derived from soybeans and soy-based food products, it has been the subject of extensive scientific investigation for its diverse and pleiotropic pharmacological properties.[3] At the core of its biological activity is a dual pharmacological identity. On one hand, Genistein functions as a Selective Estrogen Receptor Modulator (SERM), exhibiting a structural similarity to endogenous estrogen that allows it to bind to estrogen receptors, with a notable preference for the beta subtype (ERβ).[1] On the other hand, it acts as a broad-spectrum inhibitor of critical cellular enzymes, most notably protein tyrosine kinases (PTKs) and DNA topoisomerase II, which are fundamental to cell signaling, proliferation, and survival.[1]

This multifaceted mechanism of action underpins its investigation across a broad therapeutic landscape. Preclinical and clinical research has focused heavily on its potential role in the prevention and treatment of hormone-dependent cancers, particularly those of the breast and prostate, as well as in the management of postmenopausal conditions, including vasomotor symptoms and osteoporosis.[5] Emerging evidence also points to potential applications in improving cardiovascular health and offering neuroprotection against degenerative diseases.[6]

Despite its potent in vitro activity, the clinical development and therapeutic application of Genistein are confronted by a significant challenge: its low oral bioavailability. Following ingestion, Genistein undergoes extensive first-pass metabolism in the intestine and liver, resulting in systemic concentrations of the active, unconjugated (aglycone) form that are often far below those required to elicit the enzymatic inhibition observed in laboratory settings.[10] This pharmacokinetic profile creates a critical disconnect between preclinical promise and clinical reality, suggesting that its effects in humans at dietary intake levels are likely mediated by high-affinity targets such as ERβ.

Furthermore, the safety profile of Genistein is complex and dose-dependent. While generally well-tolerated in human trials, its estrogenic activity raises significant concerns about its potential for endocrine disruption, making it contraindicated in individuals with hormone-sensitive conditions.[12] The global regulatory landscape reflects this scientific ambiguity, with Genistein being treated variously as a food component, a dietary supplement, or a cosmetic ingredient with specified concentration limits, underscoring the lack of a unified consensus on its risk-benefit profile.[14] This monograph provides a comprehensive synthesis and critical analysis of the current scientific evidence pertaining to the chemistry, pharmacology, therapeutic potential, and safety of Genistein.

1.0 Introduction and Chemical Profile

This section establishes the foundational knowledge of Genistein, from its historical discovery to its chemical properties and natural distribution. It sets the stage for understanding its biological activity by first defining what the molecule is, where it comes from, and how it is obtained.

1.1 Historical Context and Discovery

Genistein has been a subject of scientific interest for over a century. It was first isolated in 1899 from the dyer's broom plant, Genista tinctoria, a member of the Fabaceae family, from which its chemical name is derived.[2] The definitive elucidation of its chemical structure occurred in 1926, when its composition was found to be identical to another isolated compound known as prunetol. This foundational work was followed by its first successful chemical synthesis in 1928, marking the beginning of its journey from a simple plant isolate to a molecule of significant pharmacological interest.[2] This long history underscores its enduring presence in the fields of natural product chemistry and pharmacology.

1.2 Chemical Identification and Nomenclature

To uniquely identify Genistein and avoid ambiguity in scientific literature, a standardized set of nomenclature and identifiers has been established.

• Chemical Name: 4',5,7-Trihydroxyisoflavone [2]
• IUPAC Name: 5,7-dihydroxy-3-(4-hydroxyphenyl)chromen-4-one [1]
• DrugBank ID: DB01645 [1]
• CAS Number: 446-72-0 [1]
• Synonyms: Prunetol, Genisteol, Phytoestrogen, Soy isoflavone [4]
• Molecular Formula: C15​H10​O5​ [1]
• Average Molecular Weight: 270.24 g/mol [4]

1.3 Molecular Structure and Physicochemical Properties

Genistein is classified as an isoflavonoid, a subclass of flavonoid compounds. Its core chemical structure consists of two aromatic rings (designated A and B) that are connected by a three-carbon bridge which forms a heterocyclic pyran ring (C).[16] Specifically, it is a 7-hydroxyisoflavone that features additional hydroxyl groups at positions 5 and 4' on the chromen-4-one skeleton.[1] This arrangement of hydroxyl groups is critical to its biological activity, particularly its ability to interact with estrogen receptors and the active sites of various enzymes.

The physicochemical properties of Genistein are fundamental to understanding its behavior in biological systems, particularly its absorption and distribution. It typically presents as a solid, appearing as a white to light yellow or light orange powder or crystal.[4] One of its most defining characteristics is its poor solubility in water, which presents a significant challenge for its formulation and bioavailability.[4] Conversely, it is soluble in polar organic solvents such as dimethyl sulfoxide (DMSO), acetone, and ethanol.[4] The molecule is also noted to be sensitive to light and heat, which has implications for its storage and handling.[4]

Property	Value / Description	Source(s)
IUPAC Name	5,7-dihydroxy-3-(4-hydroxyphenyl)chromen-4-one	1
CAS Number	446-72-0	1
DrugBank ID	DB01645	1
Molecular Formula	C15​H10​O5​	1
Molecular Weight	270.24 g/mol	19
Physical State	Solid	4
Appearance	White to light yellow/orange powder or crystal	4
Solubility	Insoluble in water; Soluble in DMSO, ethanol, acetone	4
Stability	Light and heat sensitive	4

1.4 Natural Occurrences and Dietary Sources

1.4.1 Primary Sources: Soybeans and Legumes

Genistein is a secondary metabolite found in a variety of plants, but its most concentrated and common dietary source is the soybean (Glycine max).[2] Soy-based foods contain the highest levels of Genistein among all isoflavones, with significant variability in concentration depending on the product. For instance, textured soy flour, soy protein isolates, and traditional fermented products like natto, tempeh, and miso are particularly rich sources.[12] Other leguminous plants also contain Genistein, albeit in smaller quantities, including lupin, fava beans, chickpeas, and kudzu root.[2] It is also present in red clover and has been identified in the root-tuber of

Flemingia vestita, a plant used in traditional medicine.[2]

1.4.2 Genistin: The Glucoside Precursor

In its natural state within plants, Genistein does not typically exist as a free molecule. Instead, it is predominantly found in its glycoside form, known as Genistin, where a glucose molecule is attached to the core isoflavone structure (specifically, as Genistein 7-O-beta-D-glucoside).[4] This glycoside form is biologically inactive. The conversion to the active form is a critical step that occurs during digestion. Hydrolysis, mediated by β-glucosidase enzymes present in human saliva and the small intestine, as well as enzymes produced by the colonic microbiota, cleaves the sugar molecule from Genistin.[2] This process releases the biologically active aglycone, Genistein, which is the form that is subsequently absorbed into the bloodstream.[24]

This conversion process is a pivotal determinant of Genistein's ultimate bioactivity. The efficiency of this hydrolysis step can vary significantly among individuals, depending on factors such as the composition and health of their gut microbiome and the activity of their digestive enzymes. Consequently, the same dietary intake of a soy product containing Genistin can result in markedly different systemic exposures to the active Genistein aglycone. This variability introduces a significant confounding factor in epidemiological studies that attempt to link soy consumption to health outcomes and helps to explain the large interindividual variations observed in pharmacokinetic analyses.[10] The distinction between the consumed precursor (Genistin) and the active molecule (Genistein) is therefore central to understanding its pharmacology.

1.4.3 Extraction and Synthesis Methodologies

For research, supplementation, and commercial purposes, Genistein must be isolated from its natural sources or synthesized chemically.

• Extraction from Natural Sources: The standard method for isolating Genistein from soybeans involves a multi-step process. First, defatted soy flour is extracted with an organic solvent, with 70% ethanol often being an optimal choice.[26] The resulting extract contains a mixture of isoflavone glucosides. This extract then undergoes acid hydrolysis (e.g., with hydrochloric acid) to convert the glucosides (Genistin) into their aglycone forms (Genistein).[26] Because the aglycones are much less soluble in water than their glucoside precursors, adding water to the hydrolyzed alcoholic solution causes the Genistein to crystallize and precipitate, allowing for its collection.[26] More advanced and potentially more economical methods are also being explored, such as fermentation-based bioconversion using microorganisms like Streptomyces roseolus to perform the hydrolysis in situ, or using purified enzymes for more specific and controlled conversion.[28]
• Chemical Synthesis: As first demonstrated in 1928, Genistein can also be produced through total chemical synthesis.[2] Modern organic chemistry techniques, such as the Suzuki-Miyaura coupling reaction, have been employed to synthesize not only Genistein itself but also a wide range of structural analogues. This approach is invaluable for research, allowing scientists to probe structure-activity relationships and develop novel derivatives with potentially enhanced potency or improved pharmacokinetic properties.[30]

2.0 Pharmacology and Multifaceted Mechanisms of Action

The pharmacological profile of Genistein is exceptionally complex and pleiotropic, characterized by its ability to interact with multiple, distinct molecular targets within the cell. This multifaceted activity stems primarily from two parallel mechanisms: its function as a hormone-mimicking Selective Estrogen Receptor Modulator (SERM) and its role as a direct inhibitor of key cellular enzymes, particularly protein tyrosine kinases. The interplay between these mechanisms, which are often dependent on the concentration of Genistein, gives rise to its diverse and sometimes paradoxical biological effects.

2.1 Dual Role as a Selective Estrogen Receptor Modulator (SERM)

2.1.1 Structural Homology with 17-β-Estradiol

The foundation of Genistein's hormonal activity lies in its molecular structure. As an isoflavone, its chemical architecture bears a notable resemblance to that of the primary endogenous human estrogen, 17-β-estradiol.[2] This structural homology allows Genistein to fit into the ligand-binding domain of estrogen receptors (ERs), thereby acting as a phytoestrogen—a plant-derived compound with estrogen-like activity. Upon binding, it can modulate the activity of the receptor and alter the transcription of estrogen-responsive genes, mimicking or blocking the effects of endogenous estrogen.[6]

2.1.2 Receptor Binding Affinity: ERβ Preference

A critical and defining feature of Genistein's SERM activity is its significant binding preference for the beta subtype of the estrogen receptor (ERβ) over the alpha subtype (ERα).[5]

In vitro competitive binding assays have demonstrated that Genistein has a 20- to 30-fold higher affinity for ERβ compared to ERα.[32] This selectivity is of profound pharmacological importance. The two ER subtypes have different tissue distributions and can mediate different, sometimes opposing, physiological effects. ERα is predominantly associated with proliferative effects in the uterus and mammary gland, while ERβ is more prevalent in tissues such as bone, skin, the cardiovascular system, and the brain, and is often associated with anti-proliferative and differentiating signals.[5] By preferentially activating ERβ, Genistein has the potential to elicit beneficial estrogenic effects in certain tissues (e.g., maintaining bone density) while avoiding the potentially harmful proliferative stimulation in others (e.g., the breast and uterus) that is associated with non-selective estrogen agonists.[5]

2.1.3 Downstream Genomic and Non-Genomic Effects

Upon binding to ERs, Genistein can initiate a cascade of downstream events. It functions as a partial agonist for ERβ, capable of eliciting 60-70% of the maximal response of estradiol.[5] This interaction alters the receptor's conformation, leading to the recruitment of co-activator or co-repressor proteins and subsequent modulation of gene transcription in the cell nucleus.[6]

However, the nature of this effect is highly context-dependent, particularly with respect to concentration. In ER-positive cells, Genistein often exhibits a biphasic or dualistic effect: at lower concentrations (typically below 5 μM), it tends to act as an estrogen agonist, promoting cell proliferation. At higher concentrations (often above 10 μM), it can act as an estrogen antagonist, competitively blocking the binding of more potent endogenous estrogens and inhibiting proliferation.[34] This dose-dependent duality is a recurring theme in its pharmacology and is essential for interpreting the seemingly contradictory results reported across different studies.

2.2 Inhibition of Cellular Kinases and Enzymes

2.2.1 Broad-Spectrum Tyrosine Kinase Inhibition

Independent of its hormonal activity, Genistein is a potent and well-characterized inhibitor of protein tyrosine kinases (PTKs).[1] Tyrosine kinases are a large family of enzymes that play a central role in cellular signal transduction, controlling processes such as cell growth, differentiation, migration, and survival. Many of these kinases, when dysregulated, function as oncogenes. Genistein has been shown to inhibit a broad range of PTKs, including the Epidermal Growth Factor Receptor (EGFR), platelet-derived growth factor receptor (PDGFR), and non-receptor tyrosine kinases such as pp60v-Src and pp110gag-fes.[20]

The mechanism of this inhibition is competitive with respect to adenosine triphosphate (ATP). Genistein binds to the ATP-binding pocket of the kinase's catalytic domain, thereby preventing the transfer of a phosphate group to tyrosine residues on substrate proteins.[35] This action effectively shuts down the signaling cascade initiated by the kinase. Notably, this inhibitory activity is highly specific for tyrosine kinases, with studies showing it has minimal effect on serine- and threonine-specific protein kinases.[35]

2.2.2 Inhibition of DNA Topoisomerase II

Another major non-hormonal mechanism of Genistein is its ability to inhibit DNA topoisomerase II.[1] This enzyme is essential for managing the topological state of DNA during replication, transcription, and chromosome segregation. By inhibiting topoisomerase II, Genistein can introduce DNA strand breaks and interfere with the successful completion of the cell cycle, particularly in rapidly dividing cells. This mechanism is a hallmark of several established chemotherapeutic agents and contributes significantly to Genistein's antineoplastic properties, leading to cell cycle arrest and the induction of apoptosis.

2.3 Modulation of Intracellular Signaling Pathways

The upstream actions of Genistein on ERs and key enzymes trigger a cascade of downstream effects on numerous intracellular signaling pathways that govern cell fate. By modulating these critical networks, Genistein can exert profound control over cellular processes central to cancer progression and other pathologies. Key pathways affected include:

• PI3K/Akt/mTOR: A central pathway regulating cell growth, proliferation, and survival. Genistein often downregulates this pathway, contributing to its anti-proliferative effects.[7]
• MAPK/ERK: A pathway crucial for transmitting signals from cell surface receptors to the nucleus to control gene expression and cell division. Genistein's modulation of this pathway can be complex, but it often leads to inhibition of proliferation.[7]
• JAK/STAT: A primary signaling route for many cytokines and growth factors, involved in immunity, cell growth, and apoptosis. Genistein can interfere with this pathway, contributing to its anti-inflammatory and anticancer effects.[7]
• NF-κB: A key regulator of the inflammatory response and cell survival. Genistein is a known inhibitor of NF-κB activation, which is a major component of its anti-inflammatory and pro-apoptotic activity.[7]
• Wnt/β-catenin: A pathway fundamental to development and implicated in cancer stem cell maintenance. Genistein can modulate this pathway to inhibit tumor progression.[7]

These modulations translate into concrete cellular outcomes. Genistein has been shown experimentally to induce cell cycle arrest, typically at the G2/M or G1/S transition points, by altering the expression and activity of regulatory proteins like cyclins and cyclin-dependent kinases (CDKs).[1] Furthermore, it robustly

induces apoptosis (programmed cell death) by shifting the cellular balance towards pro-apoptotic proteins (e.g., Bax, cleaved caspases) and away from anti-apoptotic proteins (e.g., Bcl-2).[7] In the context of cancer, it has also been shown to

inhibit angiogenesis, the formation of new blood vessels necessary for tumor growth, and to suppress metastasis by reducing cancer cell invasion and migration.[7]

2.4 Antioxidant and Anti-inflammatory Properties

In addition to its effects on signaling and enzyme activity, Genistein possesses potent antioxidant and anti-inflammatory properties. It can directly scavenge free radicals and protect cellular components like DNA, proteins, and lipids from oxidative damage.[1] It also exerts an indirect antioxidant effect by upregulating the expression of endogenous antioxidant enzymes, such as superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx), often via activation of the Nrf2 signaling pathway.[37] Its anti-inflammatory actions are closely linked to its inhibition of the NF-κB pathway, which reduces the production of pro-inflammatory cytokines and other mediators.[3]

A critical consideration when evaluating Genistein's multifaceted pharmacology is the "mechanism-concentration mismatch." The various mechanisms of action are triggered at different concentration thresholds. Its high-affinity binding to ERβ, for instance, can occur at the low nanomolar concentrations that may be achievable through a soy-rich diet. In contrast, the effective inhibition of most tyrosine kinases and topoisomerase II, as demonstrated in in vitro experiments, typically requires much higher micromolar concentrations.[20] This discrepancy is fundamental to understanding its effects in humans. The biological outcomes of dietary soy consumption are likely dominated by Genistein's SERM activity. To achieve the potent, broad-spectrum enzymatic inhibition seen in laboratory studies, which is responsible for many of its dramatic anti-cancer effects, would likely require pharmacological dosing or advanced drug delivery systems capable of bypassing its extensive first-pass metabolism. This distinction helps to explain the often-observed biphasic effects, where low doses may be mildly estrogenic or even pro-proliferative in some contexts, while high doses are clearly anti-proliferative and cytotoxic.

Mechanism Category	Specific Target / Pathway	Mode of Action	Primary Cellular Consequence	Source(s)
SERM Activity	Estrogen Receptor β (ERβ)	Partial Agonist (High Affinity)	Altered transcription of estrogen-responsive genes	5
	Estrogen Receptor α (ERα)	Agonist/Antagonist (Low Affinity)	Dose-dependent modulation of cell proliferation	32
Enzyme Inhibition	Protein Tyrosine Kinases (e.g., EGFR, Src)	Competitive ATP Inhibitor	Inhibition of cell growth signaling, proliferation, and survival	20
	DNA Topoisomerase II	Inhibition of enzyme activity	Induction of DNA damage, cell cycle arrest, and apoptosis	1
Signaling Pathway Modulation	PI3K/Akt/mTOR	Downregulation	Inhibition of cell growth and survival	7
	NF-κB	Inhibition of activation	Reduced inflammation, promotion of apoptosis	7
	JAK/STAT	Inhibition of signaling	Modulation of immune response and cell proliferation	7

3.0 Pharmacokinetics: Absorption, Distribution, Metabolism, and Excretion (ADME)

The pharmacokinetic profile of Genistein is a critical determinant of its in vivo efficacy and is characterized by a significant paradox: while the compound is well-absorbed from the gastrointestinal tract, the systemic bioavailability of its biologically active form is notably low. Understanding the processes of its absorption, distribution, metabolism, and excretion (ADME) is essential for bridging the gap between its potent in vitro activities and its observed effects in clinical settings.

3.1 Absorption Dynamics and Intestinal Metabolism

Human exposure to Genistein occurs primarily through the ingestion of its glycoside precursor, Genistin, found in soy-based foods.[4] The journey to bioactivity begins in the digestive tract. A portion of Genistin is hydrolyzed by β-glucosidases in the mouth and small intestine, releasing the absorbable aglycone, Genistein.[25] The majority, however, passes to the colon, where it is acted upon by the gut microbiota, which efficiently cleaves the glucose moiety.[2]

The absorption of the released Genistein aglycone is relatively rapid and appears to follow a biphasic pattern. An initial, smaller absorption phase occurs in the small intestine, accounting for approximately 10% of the total, followed by a larger, delayed absorption phase in the large intestine, which accounts for the remaining 90%.[40] This biphasic absorption is reflected in plasma concentration profiles, which typically show a peak concentration (

Tmax​) occurring around 6 hours after ingestion of a soy-containing meal, though some studies with purified Genistein report a shorter Tmax​ of less than 2 hours.[2]

3.2 The Bioavailability Challenge: Extensive First-Pass Metabolism

The central feature of Genistein's pharmacokinetics is its low oral bioavailability, which is not due to poor absorption but rather to extensive first-pass metabolism.[10] As soon as the Genistein aglycone is absorbed by intestinal epithelial cells, it is rapidly and efficiently conjugated by phase II metabolic enzymes. The primary metabolic pathways are glucuronidation (via UDP-glucuronosyltransferases) and sulfation (via sulfotransferases), which attach glucuronic acid or sulfate groups to the hydroxyl moieties of the Genistein molecule.[41] This conjugation process also occurs extensively in the liver after the absorbed Genistein travels through the portal vein.

This metabolic transformation has profound consequences for Genistein's bioactivity. The resulting glucuronide and sulfate conjugates are generally considered to be biologically inactive and are more water-soluble, facilitating their excretion. As a result, the concentration of the free, active Genistein aglycone that reaches systemic circulation is very low. Pharmacokinetic studies in rodent models vividly illustrate this disparity: the absolute bioavailability of free Genistein aglycone was reported to be as low as 6.8% to <15%, whereas the bioavailability of total Genistein (the sum of the free aglycone and its conjugated metabolites) was high, ranging from over 55% to nearly 90%.[11] This indicates that while the vast majority of the ingested dose is absorbed, only a small fraction exists in its active form in the bloodstream at any given time. This "bioavailability paradox" is the single most important factor limiting the clinical translation of many of Genistein's potent

in vitro effects.

3.3 Distribution, Tissue Accumulation, and Elimination

Once in circulation, Genistein and its more abundant conjugates are distributed throughout the body. Studies suggest that these compounds tend to accumulate primarily in the gastrointestinal tract and the liver.[11] This localized concentration is largely a result of significant enterohepatic recycling. In this process, the conjugated metabolites are excreted from the liver into the bile, enter the intestine, where gut bacteria can de-conjugate them back to the active Genistein aglycone, which is then reabsorbed into the portal circulation.[11] This recycling mechanism is evidenced by the appearance of double peaks in plasma concentration-time profiles and contributes to a very long apparent terminal half-life for total Genistein, which has been reported to be as long as 46 hours after oral administration.[11] This recycling creates a sustained, albeit low-level, exposure of the intestinal and hepatic tissues to the active compound, which may have important implications for its local effects in these organs, such as in the chemoprevention of colorectal or liver cancers. In contrast, distribution to other tissues, including reproductive organs, does not appear to be concentrated relative to plasma levels.[11]

3.4 Factors Influencing Pharmacokinetic Variability

The ADME profile of Genistein is subject to significant interindividual variability, which contributes to the inconsistent outcomes often seen in clinical trials.[10] Several factors are known to influence its pharmacokinetics:

• Gut Microbiota: The composition and metabolic activity of an individual's gut microbiome are critical for the initial conversion of Genistin to Genistein and for the de-conjugation that drives enterohepatic recycling. Differences in microbial populations can lead to substantial differences in the amount of active Genistein absorbed.[40]
• Host Factors: Age and general health status have been shown to affect the bioavailability of isoflavones, with bioavailability reported to be higher in children than in adults and higher in healthy individuals compared to those with underlying health conditions.[40]
• Food Matrix: The food in which Genistein is consumed can also impact its absorption. For example, the Tmax​ can be significantly extended when Genistein is administered as part of a soy protein matrix compared to when it is given as a purified compound.[11]

4.0 Therapeutic Applications and Clinical Evidence

Genistein's unique, multi-target pharmacology has prompted extensive investigation into its potential therapeutic applications across a range of human diseases. The evidence base, however, varies significantly in quality and consistency, from robust clinical trial data in some areas to preliminary or conflicting findings in others. A critical evaluation reveals a clear hierarchy of evidence for its clinical utility.

4.1 Oncology: A Chemopreventive and Therapeutic Agent

The potential of Genistein in cancer prevention and treatment has been a primary focus of research, driven by epidemiological observations and its potent effects on cancer cell biology in vitro.

4.1.1 Breast and Prostate Cancer

Much of the initial interest in Genistein stemmed from epidemiological studies observing that populations in Asian countries, which traditionally consume a soy-rich diet, have a lower incidence of hormone-dependent cancers like breast and prostate cancer compared to Western populations.[4] This association suggested a potential chemopreventive role for soy isoflavones. The proposed mechanisms are multifaceted, involving Genistein's ability to modulate estrogen and androgen receptor signaling, inhibit tyrosine kinases like EGFR that drive cell growth, induce apoptosis, and cause cell cycle arrest in cancer cells.[7]

However, the role of Genistein in hormone-sensitive cancers is complex and not without controversy. Its estrogenic activity gives rise to a dual effect: while it may be protective in some contexts, several studies have raised concerns that at low, diet-achievable concentrations, it could potentially stimulate the growth of existing estrogen-receptor-positive (ER+) tumors or interfere with the efficacy of endocrine therapies like tamoxifen.[16] Long-term exposure to low doses has been shown in preclinical models to induce endocrine resistance.[34] This complexity highlights the critical importance of dose, timing of exposure (e.g., pre- vs. post-menopausal), and tumor characteristics. Clinical investigation has been undertaken to clarify these roles, including a completed Phase II trial (NCT00290758) evaluating Genistein for breast cancer prevention in high-risk women and studies assessing its effects on biomarkers in patients with localized prostate cancer.[44]

4.1.2 Gastrointestinal, Cervical, and Other Cancers

Research has extended beyond hormone-dependent cancers to other malignancies. Preclinical studies have demonstrated Genistein's potential as a therapeutic agent for gastric, colorectal, liver, and cervical cancers.[31] In these models, its anticancer activity is primarily attributed to its non-hormonal mechanisms, such as the inhibition of key signaling pathways like PI3K/Akt and MAPK/ERK, leading to reduced cell proliferation and survival, and the induction of apoptosis.[39]

4.1.3 Synergistic Potential

An important area of investigation is Genistein's potential to act as a chemosensitizer or radiosensitizer. In vitro and in vivo studies have shown that Genistein can work synergistically with conventional anticancer treatments, including chemotherapeutic drugs like adriamycin and docetaxel, as well as with ionizing radiation.[31] By inhibiting survival pathways and cell cycle checkpoints, Genistein may lower the threshold for cancer cell death induced by these standard therapies, potentially enhancing their efficacy or allowing for lower, less toxic doses.

4.2 Women's Health and Endocrinology

Genistein's SERM activity makes it a natural candidate for conditions related to estrogen deficiency, particularly those associated with menopause.

4.2.1 Management of Menopausal Vasomotor Symptoms

Genistein has been widely studied as an alternative to hormone replacement therapy (HRT) for the alleviation of vasomotor symptoms such as hot flashes and night sweats. Evidence from multiple clinical trials and meta-analyses suggests that supplementation with Genistein or mixed soy isoflavones can significantly reduce the frequency and severity of these symptoms compared to placebo.[2] However, the magnitude of this effect is often modest, and results across studies have been somewhat inconsistent, leading to a general classification of the evidence as "Possibly Effective".[50]

4.2.2 Osteoporosis Prevention and Bone Mineral Density (BMD)

The strongest and most consistent clinical evidence for Genistein's therapeutic benefit lies in its effects on bone health in postmenopausal women. The decline in estrogen during menopause accelerates bone loss, leading to osteopenia and osteoporosis. Several high-quality, randomized, double-blind, placebo-controlled trials have demonstrated that daily supplementation with 54 mg of purified Genistein aglycone for periods of one to three years has significant positive effects on bone mineral density.[8] These trials have shown that Genistein not only slows the rate of bone loss but can also lead to a statistically significant increase in BMD at critical sites like the lumbar spine and femoral neck, compared to continued loss in placebo groups.[8] The mechanism is believed to be its estrogen-like (ERβ-mediated) action on bone cells, which suppresses the activity of bone-resorbing osteoclasts and may stimulate bone-forming osteoblasts.[4]

4.3 Cardiovascular and Metabolic Health

4.3.1 Effects on Lipid Profiles and Endothelial Function

Genistein has been investigated for its potential to reduce cardiovascular risk in postmenopausal women, serving as a possible alternative to HRT.[1] Some clinical trials have reported beneficial effects, including improvements in endothelial function, as measured by an increased ratio of nitric oxide to endothelin, and favorable changes in blood lipid profiles.[5] However, the evidence is not uniformly positive. In a comprehensive review, the European Food Safety Authority (EFSA) panel concluded that there was insufficient evidence to establish a cause-and-effect relationship between the consumption of soy isoflavones and the maintenance of normal blood LDL-cholesterol levels.[2]

4.3.2 Potential Roles in Diabetes and Glucose Metabolism

There is emerging evidence from both preclinical and clinical studies suggesting that Genistein may have beneficial effects on glucose homeostasis. It has been shown to improve insulin resistance and markers of inflammation in patients with non-alcoholic fatty liver disease and in postmenopausal women with type 2 diabetes.[6] The proposed mechanisms include the inhibition of islet tyrosine kinase activity and modulation of insulin release.[6]

4.4 Emerging Research Areas: Neuroprotection and Antiviral/Antiparasitic Activity

Neuroprotection

A promising new avenue of research is the potential role of Genistein in neurodegenerative diseases. A recent bicentric, double-blind, placebo-controlled clinical trial (the GENIAL trial, NCT01982578) evaluated the effects of 120 mg of Genistein daily for 12 months in patients with prodromal Alzheimer's disease.[55] The results, while preliminary, were encouraging. The Genistein-treated group showed a stabilization of amyloid-beta deposition in the anterior cingulate gyrus, whereas the placebo group showed an increase. Furthermore, the treated patients demonstrated a significant improvement in cognitive scores on two of the administered tests, with a trend towards improvement in others.[55] This is supported by preclinical animal models where Genistein has shown cognitive benefits.[9]

Antiviral/Antiparasitic Activity

Genistein has also demonstrated direct antimicrobial activity. In vitro studies have shown that it can inhibit HIV-1 replication by interfering with DNA synthesis in resting CD4+ T cells.[20] Additionally, it has a well-documented history as an antihelmintic agent. It has been identified as the active component in

Flemingia vestita, a plant traditionally used to treat parasitic worm infections, and has shown efficacy against common liver flukes, pork trematodes, and poultry cestodes.[1]

Indication	Study Identifier / Reference	Study Design	Dose and Duration	Key Outcomes	Source(s)
Postmenopausal Osteoporosis	Marini et al., 2007 (NCT00355953)	Randomized, Double-Blind, Placebo-Controlled	54 mg/day for 24 months	Significant increase in BMD at lumbar spine and femoral neck vs. placebo; Favorable effects on bone turnover markers.	8
Postmenopausal Osteoporosis	Arcoraci et al., 2017	Post-hoc analysis of a multicenter RCT	54 mg/day for 24 months	In osteoporotic subgroup, BMD increased in genistein group and decreased in placebo group; Prevalence of osteoporosis decreased from 31% to 12% in genistein group.	45
Breast Cancer Prevention	NCT00290758	Randomized Phase II Trial	Not specified	To study how well genistein works in preventing breast cancer in women at high risk. (Status: Completed)	44
Prodromal Alzheimer's Disease	GENIAL Trial (NCT01982578)	Double-Blind, Placebo-Controlled	120 mg/day for 12 months	Stabilized amyloid-beta deposition in anterior cingulate gyrus vs. increase in placebo; Significant improvement in 2 cognitive tests.	55

5.0 Toxicology, Safety Profile, and Drug Interactions

A thorough assessment of Genistein's safety profile is essential for determining its therapeutic index and appropriate use. The evaluation reveals a complex picture where Genistein is generally well-tolerated at doses used in human clinical trials, yet preclinical studies raise significant toxicological concerns related to its potent endocrine-disrupting capabilities.

5.1 Preclinical Toxicology and Reproductive Safety

Animal studies have been crucial in defining the toxicological profile of Genistein. In acute toxicity studies, it exhibits a low order of toxicity, indicating a wide margin of safety for single high doses.[57] However, repeated-dose studies reveal more significant, dose-dependent effects.

In subchronic and chronic dietary studies in rats, high doses of Genistein (e.g., 500 mg/kg/day) were associated with several systemic effects, including decreased food consumption and body weight gain, mild hematological changes (decreased red blood cell parameters), and evidence of mild hepatic effects, such as minimal bile duct proliferation.[57]

The most prominent and consistent findings in preclinical toxicology are related to Genistein's estrogenic activity. Histological changes have been observed in the reproductive organs of both sexes. In females, these include effects on the ovaries and uterus, while in males, changes have been noted in the epididymides and prostate.[57] A multigenerational study in Sprague-Dawley rats exposed to dietary Genistein at concentrations of 100 or 500 ppm found several adverse effects, including depressed preweaning body weight gains, an increased incidence of male mammary gland hyperplasia, and kidney lesions (renal tubule mineralization and inflammation).[18] However, the study did not find clear evidence of overt reproductive toxicity or adverse effects that were imprinted and carried over into unexposed subsequent generations.[18]

These findings have led to the classification of Genistein as a potential endocrine disruptor.[12] Its estrogenic properties are the primary driver of these toxicological observations. This presents a fundamental challenge in safety assessment, as it becomes necessary to distinguish between an expected, hormonally-mediated

functional change (e.g., an increase in uterine weight, which is an expected outcome for any estrogenic compound) and a truly adverse toxicological effect. The authors of one chronic toxicity study concluded that most of the treatment-related findings were functional in nature and, in that context, were not considered adverse effects.[57] This nuance complicates the establishment of a single No-Observed-Adverse-Effect Level (NOAEL), as the safety threshold is critically dependent on the specific endpoint being measured and the physiological context. Furthermore, some research suggests Genistein may also act as an "obesogen," a compound that can interfere with lipid metabolism and promote adipogenesis, further highlighting its complex endocrine-disrupting potential.[58]

5.2 Human Safety Profile and Adverse Events in Clinical Trials

In human clinical trials, Genistein supplementation, typically at doses around 54 mg per day, is generally regarded as safe and well-tolerated.[56] The most frequently reported adverse events are minor gastrointestinal side effects, such as stomach upset.[8] A key safety endpoint for any estrogenic compound is its effect on the endometrium. Reassuringly, a 24-month clinical trial in postmenopausal women found that 54 mg/day of Genistein did not cause an increase in endometrial thickness, suggesting a low risk of uterine hyperplasia at this dose.[8]

However, the human safety data is not without a significant and concerning contradiction. While epidemiological studies in Asian populations often associate high soy intake with positive health outcomes, an observational study using data from the U.S. National Health and Nutrition Examination Survey (NHANES) found a paradoxical association. In this large U.S. cohort, higher urinary concentrations of Genistein were significantly associated with higher all-cause mortality.[56] The mortality rate in the highest quartile of urinary Genistein was more than double that of the lowest quartile. This stark discrepancy may reflect fundamental differences in the context of consumption. In traditional Asian diets, Genistein is consumed as part of a whole-food matrix (e.g., tofu, tempeh) within a broader healthy lifestyle pattern. In the U.S. population, high urinary levels may originate from the consumption of processed foods fortified with soy protein isolates or from high-dose dietary supplements, taken within a different dietary and lifestyle context. This finding underscores that the health effects of Genistein may not be separable from its source and that its safety profile could differ substantially when consumed as a purified supplement versus as a component of whole foods.

5.3 Contraindications and High-Risk Populations

Given its well-established estrogen-like activity, the primary contraindication for Genistein supplementation is the presence of any hormone-sensitive condition.[13] Its use should be avoided by individuals with a history of:

• Breast cancer
• Uterine cancer
• Ovarian cancer
• Endometriosis
• Uterine fibroids

In these conditions, the estrogenic properties of Genistein could potentially exacerbate the disease.[13] Additionally, due to a lack of sufficient safety data, the use of Genistein supplements during pregnancy and breastfeeding is not recommended.[13]

5.4 Comprehensive Review of Drug-Drug Interactions

Genistein has the potential to engage in a vast number of drug-drug interactions, primarily by influencing the activity of drug-metabolizing enzymes and transporters. As a substrate and modulator of various cytochrome P450 (CYP) enzymes, it can alter the pharmacokinetics of many conventional drugs.

The interactions can be broadly categorized:

• Genistein affecting other drugs: Genistein can inhibit the metabolism of certain drugs, leading to their increased serum concentration and potential toxicity. For example, it may decrease the metabolism of drugs like abrocitinib, acetohexamide, and atorvastatin.[6] It may also decrease the excretion of certain drugs, such as afatinib and allopurinol, which could also result in higher serum levels.[6]
• Other drugs affecting Genistein: Conversely, the metabolism of Genistein can be altered by other drugs. Its metabolism can be increased by substances like abatacept and albendazole, potentially reducing its efficacy, or decreased by substances like acyclovir and azathioprine, potentially increasing its systemic exposure.[6]
• Pharmacodynamic interactions: As a phytoestrogen, Genistein may theoretically interfere with the effects of estrogen-based medications, such as hormone replacement therapy or oral contraceptives, through competitive inhibition at estrogen receptors. The clinical significance of this interaction is currently unknown but warrants caution.[60]
• Other interactions: A specific interaction has been noted with caffeine, where Genistein might slow down the body's clearance of caffeine, potentially increasing its stimulating effects.[13]

The extensive list of potential interactions underscores the importance of consulting a healthcare provider before combining Genistein supplements with any prescription or over-the-counter medications.

Interacting Drug / Class	Potential Effect	Mechanism	Clinical Implication / Recommendation	Source(s)
Abiraterone	Increased serum concentration of Genistein	Inhibition of Genistein metabolism	Monitor for potential increased effects or side effects of Genistein.	6
Acalabrutinib	Decreased serum concentration of Acalabrutinib	Induction of Acalabrutinib metabolism by Genistein	Potential for reduced efficacy of Acalabrutinib. Combination should be approached with caution.	6
Atorvastatin	Increased serum concentration of Atorvastatin	Inhibition of Atorvastatin metabolism by Genistein	Increased risk of statin-related side effects (e.g., myopathy). Monitor closely.	6
Tamoxifen (and other Estrogens)	Theoretical interference	Competitive inhibition at estrogen receptors	Genistein may antagonize or potentiate the effects of estrogenic drugs. Clinical significance is unknown.	60
Caffeine	Increased effects of caffeine	Inhibition of caffeine metabolism	May lead to increased jitteriness, insomnia, or other caffeine-related side effects.	13
Warfarin (Acenocoumarol)	Increased serum concentration of anticoagulant	Inhibition of anticoagulant metabolism	Increased risk of bleeding. Requires close monitoring of INR if used concurrently.	6

6.0 Global Regulatory Status and Future Perspectives

The regulatory status of Genistein varies considerably across the globe, a situation that directly reflects the scientific complexities and ambiguities surrounding its dual role as a common food component and a potent bioactive agent. This lack of a unified regulatory framework, coupled with significant scientific challenges, shapes the future perspectives for its development as a therapeutic agent.

6.1 Regulatory Landscape in Major Jurisdictions

• United States (FDA): In the United States, Genistein and other soy isoflavones do not have a specific, formal regulation by the Food and Drug Administration (FDA). They primarily exist in the market as components of food or as dietary supplements. While soy products are generally recognized as safe (GRAS), this designation does not specifically apply to purified, isolated Genistein.[2] As dietary supplements, products containing Genistein are not subject to the same rigorous pre-market approval process for safety and efficacy as pharmaceutical drugs.[14]
• European Union (EMA/EFSA): The European Union has adopted a more cautious and proactive approach. Genistein is generally managed under regulations for food supplements, with safety assessments conducted by the European Food Safety Authority (EFSA).[61] Notably, due to concerns about its potential endocrine-disrupting properties, the Scientific Committee on Consumer Safety (SCCS) has issued a specific opinion regarding its use in cosmetic products. The SCCS concluded that Genistein is safe for use in leave-on cosmetic products only up to a maximum concentration of 0.007%.[15] To date, no prescription drug containing Genistein as the active ingredient has been approved by the European Medicines Agency (EMA) for any indication, including the treatment of menopausal symptoms.[61]
• Australia (TGA): Australia's Therapeutic Goods Administration (TGA) regulates Genistein as a complementary medicine. It is included in the Australian Register of Therapeutic Goods (ARTG) as a permissible ingredient for use in "listed medicines".[63] This category is reserved for products considered to be of low risk, which may make therapeutic claims based on traditional use or scientific evidence for minor, self-limiting conditions.[64]

This global regulatory fragmentation is a direct consequence of the scientific ambiguity surrounding Genistein. Its status as a long-standing component of the human diet complicates efforts to regulate it strictly, yet its potent, hormone-like biological activity necessitates a level of scrutiny not typically applied to food ingredients. The different approaches taken by the US, EU, and Australia highlight the ongoing debate about how to balance consumer access with the potential risks of a bioactive compound that blurs the lines between nutrition and pharmacology.

6.2 Current Challenges and Future Research Directions

6.2.1 Overcoming Bioavailability Limitations

The most significant scientific hurdle to the clinical development of Genistein as a systemic therapeutic agent is its low oral bioavailability.[7] The extensive first-pass metabolism that converts the active aglycone into inactive conjugates means that oral administration of standard formulations is unlikely to achieve the sustained, high systemic concentrations required for many of its most potent anticancer effects, such as broad-spectrum tyrosine kinase inhibition. Therefore, a primary focus of future research must be on the development of novel formulations and drug delivery systems. Strategies being investigated include the use of nanovectors, such as nanoparticles and liposomes, which could protect Genistein from premature metabolism and enhance its delivery to target tissues.[7]

6.2.2 Clarifying Dose-Dependent and Context-Specific Effects

The second major challenge is to fully elucidate Genistein's complex, dose-dependent, and often biphasic biological effects. More long-term, prospective human studies and larger, well-designed clinical trials are urgently needed to define safe and effective therapeutic windows for different indications.[3] Key research questions that remain to be answered include:

• Resolving the safety concerns in hormone-sensitive conditions by clearly defining the concentration thresholds at which Genistein switches from being potentially pro-proliferative to anti-proliferative.
• Understanding the factors that contribute to the paradoxical mortality findings in observational studies and determining if the source of Genistein (whole food vs. isolate/supplement) modifies its long-term health effects.[56]
• Investigating the clinical relevance of its synergistic effects with conventional cancer therapies to see if it can be integrated into standard treatment protocols.

6.3 Concluding Remarks on the Therapeutic Potential of Genistein

Genistein stands as a molecule of immense scientific interest, possessing a compelling, multi-target pharmacological profile that bridges endocrinology, oncology, and cellular signaling. The cumulative evidence indicates that its most validated and clinically robust therapeutic application to date is in the preservation of bone mineral density and the prevention of osteoporosis in postmenopausal women. Its potential roles in alleviating menopausal symptoms, preventing and treating cancer, and offering neuroprotection are promising but remain more investigational, hampered by the critical challenges of low bioavailability and a complex, context-dependent safety profile.

The journey of Genistein from a simple component in a traditional diet to a precisely administered therapeutic agent is far from complete. The extensive body of research suggests that its future as a potent drug, particularly in oncology, may not lie in its use as a simple dietary supplement. Rather, its true potential may be realized by viewing it as a powerful lead compound—an ideal chemical scaffold for the rational design and synthesis of novel derivatives and for incorporation into advanced drug delivery systems. Such pharmaceutical development could harness its potent mechanisms of action while improving its pharmacokinetic properties and refining its safety profile, ultimately transforming this ancient phytoestrogen into a modern therapeutic tool.

Works cited

1. Genistein | C15H10O5 | CID 5280961 - PubChem, accessed September 27, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Genistein
2. Genistein - Wikipedia, accessed September 27, 2025, https://en.wikipedia.org/wiki/Genistein
3. Genistein: An Integrative Overview of Its Mode of Action, Pharmacological Properties, and Health Benefits, accessed September 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8315847/
4. An Overview on Genistein and its Various Formulations - Thieme Connect, accessed September 27, 2025, https://www.thieme-connect.com/products/ejournals/pdf/10.1055/a-0797-3657.pdf
5. The Therapeutic Role of Genistein in Perimenopausal and ..., accessed September 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11495164/
6. Genistein: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed September 27, 2025, https://go.drugbank.com/drugs/DB01645
7. Cellular and Molecular Mechanisms Modulated by Genistein in ..., accessed September 27, 2025, https://www.mdpi.com/1422-0067/26/3/1114
8. Effects of the Phytoestrogen Genistein on Bone Metabolism in Osteopenic Postmenopausal Women: A Randomized Trial: Annals of Internal Medicine - ACP Journals, accessed September 27, 2025, https://www.acpjournals.org/doi/10.7326/0003-4819-146-12-200706190-00005
9. Genistein: A Potential Natural Lead Molecule for New Drug Design and Development for Treating Memory Impairment - MDPI, accessed September 27, 2025, https://www.mdpi.com/1420-3049/27/1/265
10. (PDF) Bioavailability and Pharmacokinetics of Genistein ..., accessed September 27, 2025, https://www.researchgate.net/publication/224956270_Bioavailability_and_Pharmacokinetics_of_Genistein_Mechanistic_Studies_on_its_ADME
11. Bioavailability and Pharmacokinetics of Genistein: Mechanistic ..., accessed September 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4010305/
12. Genistein: Dual Role in Women's Health - PMC, accessed September 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8472782/
13. GENISTEIN COMBINED POLYSACCHARIDE: Overview, Uses, Side Effects, Precautions, Interactions, Dosing and Reviews - WebMD, accessed September 27, 2025, https://www.webmd.com/vitamins/ai/ingredientmono-1088/genistein-combined-polysaccharide
14. public comment - Regulations.gov, accessed September 27, 2025, https://www.regulations.gov/search/comment?filter=Isoflavone
15. OPINION on Genistein and Daidzein - Public Health - European Commission, accessed September 27, 2025, https://health.ec.europa.eu/system/files/2023-08/sccs_o_263.pdf
16. Genistein: A Potent Anti-Breast Cancer Agent - MDPI, accessed September 27, 2025, https://www.mdpi.com/1467-3045/43/3/106
17. Genistein: A Review on its Anti-Inflammatory Properties - Frontiers, accessed September 27, 2025, https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.820969/full
18. Multigenerational reproductive study of genistein (Cas No. 446-72-0) in Sprague-Dawley rats (feed study) - PubMed, accessed September 27, 2025, https://pubmed.ncbi.nlm.nih.gov/18685713/
19. Genistein | CAS 446-72-0 | SCBT - Santa Cruz Biotechnology, accessed September 27, 2025, https://www.scbt.com/p/genistein-446-72-0
20. Genistein (CI-75610, NSC 36586, CAS Number: 446-72-0) | Cayman Chemical, accessed September 27, 2025, https://www.caymanchem.com/product/10005167/genistein
21. Genistein 446-72-0 | TCI AMERICA, accessed September 27, 2025, https://www.tcichemicals.com/US/en/p/G0272
22. Genistein: Significance and symbolism, accessed September 27, 2025, https://www.wisdomlib.org/concept/genistein
23. Genistein, Protein tyrosine kinase inhibitor (CAS 446-72-0) - Abcam, accessed September 27, 2025, https://www.abcam.com/en-us/products/biochemicals/genistein-protein-tyrosine-kinase-inhibitor-ab120112
24. FACT SHEET on the PHYTOESTROGEN GENISTEIN, accessed September 27, 2025, https://bcerp.org/wp-content/uploads/6_BCERC.FactSheet_Phytoestrogen_Genistein.pdf
25. Genistin - Wikipedia, accessed September 27, 2025, https://en.wikipedia.org/wiki/Genistin
26. Phytoestrogen “Genistein”: Its Extraction and Isolation from Soybean Seeds - Impactfactor, accessed September 27, 2025, http://impactfactor.org/PDF/IJPPR/7/IJPPR,Vol7,Issue6,Article15.pdf
27. US5679806A - Process for the isolation and purification of isoflavones - Google Patents, accessed September 27, 2025, https://patents.google.com/patent/US5679806A/en
28. Design and Optimization of a Novel Method for Extraction of Genistein - PMC, accessed September 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3267303/
29. Production of Daidzein and Genistein from Seed and Root Extracts of Korean Wild Soybean (Glycine soja) by Thermostable β-Galactosidase from Thermoproteus uzoniensis - MDPI, accessed September 27, 2025, https://www.mdpi.com/2076-3417/12/7/3481
30. Design, Synthesis, and Evaluation of Genistein Analogues as Anti-Cancer Agents - PMC, accessed September 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4748842/
31. Full article: Anticancer perspectives of genistein: a comprehensive review, accessed September 27, 2025, https://www.tandfonline.com/doi/full/10.1080/10942912.2023.2281257
32. Effect of Genistein As a Selective Estrogen Receptor Beta Agonist on the Expression of Calbindin-D9k in the Uterus of Immature Rats - Oxford Academic, accessed September 27, 2025, https://academic.oup.com/toxsci/article/82/2/451/1657010
33. The Therapeutic Role of Genistein in Perimenopausal and Postmenopausal Women | JCAD - The Journal of Clinical and Aesthetic Dermatology, accessed September 27, 2025, https://jcadonline.com/genistein-perimenopausal-and-postmenopausal-women/
34. Genistein induces endocrine resistance in human breast cancer by suppressing H3K27 trimethylation in, accessed September 27, 2025, https://erc.bioscientifica.com/view/journals/erc/30/2/ERC-22-0191.xml
35. Genistein, a specific inhibitor of Tyrosine-Specific protein kinases - ResearchGate, accessed September 27, 2025, https://www.researchgate.net/publication/20050624_Genistein_a_specific_inhibitor_of_Tyrosine-Specific_protein_kinases
36. Synthetic Genistein Glycosides Inhibiting EGFR Phosphorylation Enhance the Effect of Radiation in HCT 116 Colon Cancer Cells - MDPI, accessed September 27, 2025, https://www.mdpi.com/1420-3049/19/11/18558
37. Critical Review on Molecular Mechanisms for Genistein's Beneficial Effects on Health Through Oxidative Stress Reduction - MDPI, accessed September 27, 2025, https://www.mdpi.com/2076-3921/14/8/904
38. Effect of a tyrosine kinase inhibitor, genistein, on the actions of prolactin in cultured mouse mammary tissues - Oregon Health & Science University, accessed September 27, 2025, https://ohsu.elsevierpure.com/en/publications/effect-of-a-tyrosine-kinase-inhibitor-genistein-on-the-actions-of-2
39. A Comprehensive Review of Genistein's Effects in Preclinical Models of Cervical Cancer, accessed September 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10778482/
40. Absorption, distribution, metabolism, and excretion of isoflavonoids after soy intake - PubMed, accessed September 27, 2025, https://pubmed.ncbi.nlm.nih.gov/24946051/
41. Absorption and metabolism of genistein and its five isoflavone analogs in human intestinal Caco-2 model - ResearchGate, accessed September 27, 2025, https://www.researchgate.net/publication/8260621_Absorption_and_metabolism_of_genistein_and_its_five_isoflavone_analogs_in_human_intestinal_Caco-2_model
42. Molecular Mechanisms of Action of Genistein in Cancer: Recent Advances - Frontiers, accessed September 27, 2025, https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2019.01336/full
43. GENISTEIN Definition & Meaning - Dictionary.com, accessed September 27, 2025, https://www.dictionary.com/browse/genistein
44. Genistein in Preventing Breast Cancer in Women at High Risk for Breast Cancer, accessed September 27, 2025, https://prevention.cancer.gov/clinical-trials/clinical-trials-search/nct00290758
45. Recent pharmacological advances on genistein in clinical trials - PMC, accessed September 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7573176/
46. Genistein: Therapeutic and Preventive Effects, Mechanisms, and Clinical Application in Digestive Tract Tumor - PMC, accessed September 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9259214/
47. Full article: Efficacy of phytoestrogens for menopausal symptoms: a meta-analysis and systematic review - Taylor & Francis Online, accessed September 27, 2025, https://www.tandfonline.com/doi/full/10.3109/13697137.2014.966241
48. Soy isoflavones in postmenopausal women: a review of current evidence - e-Century Publishing Corporation, accessed September 27, 2025, https://e-century.us/files/ajceog/8/1/ajceog0144070.pdf
49. Genistein as Potential Therapeutic Candidate for Menopausal Symptoms and Other Related Diseases - PMC - PubMed Central, accessed September 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6864469/
50. genistein (soy): Dosing, contraindications, side effects, and pill pictures - epocrates online, accessed September 27, 2025, https://www.epocrates.com/online/drugs/alternative-medicines/821708/genistein-soy/Monograph
51. Botanicals in Postmenopausal Osteoporosis - MDPI, accessed September 27, 2025, https://www.mdpi.com/2072-6643/13/5/1609
52. Antiosteoporotic Activity of Genistein Aglycone in Postmenopausal Women: Evidence from a Post-Hoc Analysis of a Multicenter Randomized Controlled Trial, accessed September 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5331610/
53. The protective activity of genistein against bone and cartilage diseases - PubMed Central, accessed September 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9492956/
54. Genistein Supplementation and Bone Health in Breast Cancer in Rats - MDPI, accessed September 27, 2025, https://www.mdpi.com/2072-6643/16/6/912
55. Genistein effect on cognition in prodromal Alzheimer's disease patients. The GENIAL clinical trial - PMC - PubMed Central, accessed September 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9635167/
56. Genistein - Alzheimer's Drug Discovery Foundation, accessed September 27, 2025, https://www.alzdiscovery.org/uploads/cognitive_vitality_media/Genistein.pdf
57. Acute, subchronic and chronic safety studies with genistein in rats - ResearchGate, accessed September 27, 2025, https://www.researchgate.net/publication/7551511_Acute_subchronic_and_chronic_safety_studies_with_genistein_in_rats
58. The obesogenic side of Genistein - Frontiers, accessed September 27, 2025, https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2023.1308341/full
59. Genistein Combined Polysaccharide: Health Benefits, Side Effects, Uses, Dose & Precautions - RxList, accessed September 27, 2025, https://www.rxlist.com/supplements/genistein_combined_polysaccharide.htm
60. Drug Interaction Report: cholecalciferol / genistein / zinc chelazome, quinestrol - Drugs.com, accessed September 27, 2025, https://www.drugs.com/interactions-check.php?drug_list=2854-0,2778-0&professional=1
61. https://www.frontiersin.org/journals/nutrition/articles/10\.3389/fnut.2025\.1651367/xml, accessed September 27, 2025, https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2025.1651367/xml
62. SCCS Preliminary Opinion on Genistein and Daidzein - CRITICAL CATALYST, accessed September 27, 2025, https://criticalcatalyst.com/sccs-preliminary-opinion-on-genistein-and-daidzein/
63. Genistein (199015) | Therapeutic Goods Administration (TGA), accessed September 27, 2025, https://www.tga.gov.au/resources/artg/199015
64. Australia updates some Listed Medicine Ingredients - Food Compliance International, accessed September 27, 2025, https://foodcomplianceinternational.com/industry-insight/news/4458-australia-updates-some-listed-medicine-ingredients
65. Australian regulatory guidelines for complementary medicines (ARGCM) - Therapeutic Goods Administration (TGA), accessed September 27, 2025, https://www.tga.gov.au/sites/default/files/australian-regulatory-guidelines-complementary-medicines-argcm.pdf